Overexpression of STC2 has been demonstrated to contribute to poor prognosis or recurrence in colorectal (15), gastric (16) and prostate (17) cancer, as well as neuroblastoma (18) and renal cell carcinoma (8). The gene discussed is STC2; the disease is urogenital neoplasm.